Cargando…

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

INTRODUCTION: In the cardiovascular outcome trials (CVOT) EMPA-REG OUTCOME, TECOS and SAVOR-TIMI 53, empagliflozin [sodium/glucose cotransporter 2 (SGLT2) inhibitor], sitagliptin and saxagliptin [both dipeptidyl peptidase 4 (DPP4) inhibitors] + standard of care (SoC) were compared to SoC in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramos, Mafalda, Foos, Volker, Ustyugova, Anastasia, Hau, Nikco, Gandhi, Pranav, Lamotte, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848565/ https://www.ncbi.nlm.nih.gov/pubmed/31602601 http://dx.doi.org/10.1007/s13300-019-00701-3

Ejemplares similares

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
por: Ramos, Mafalda, et al.
Publicado: (2020)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease
por: Ehlers, Lars Holger, et al.
Publicado: (2021)

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
por: Balijepalli, Chakrapani, et al.
Publicado: (2018)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017)

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark
por: Ehlers, Lars H., et al.
Publicado: (2022)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Call for Comparative Effectiveness Research: Lowering A1c with Sitagliptin, Saxagliptin, or Cinnamon
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
por: Tatosian, Daniel A., et al.
Publicado: (2013)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
por: Ghetti, Gianni, et al.
Publicado: (2023)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study
por: Thomsen, Reimar W., et al.
Publicado: (2021)

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
por: Zhou, Xiao-jun, et al.
Publicado: (2019)

Implementation of Empagliflozin in Patients with Diabetes Mellitus Type 2 and Established Cardiovascular Disease: Estimation of 5-Year Survival and Costs in Sweden
por: Bernfort, Lars, et al.
Publicado: (2020)

Cost‐effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA‐REG OUTCOME trial
por: Kansal, A., et al.
Publicado: (2019)

Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease
por: Toth, Peter P
Publicado: (2014)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
por: Eliasson, Björn, et al.
Publicado: (2022)

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark
por: Thomsen, Reimar W., et al.
Publicado: (2022)

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States
por: Reifsnider, Odette, et al.
Publicado: (2020)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
por: Bain, Stephen C., et al.
Publicado: (2019)

Efficacy and safety of combination of empagliflozin and metformin with combination of sitagliptin and metformin during Ramadan: an observational study
por: Ahmed, Ibrar, et al.
Publicado: (2022)

External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions
por: Lopes, Sandra, et al.
Publicado: (2020)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease
por: Lim, Jayoung, et al.
Publicado: (2022)

Cost-Effectiveness of Semaglutide vs. Empagliflozin, Canagliflozin, and Sitagliptin for Treatment of Patients with Type 2 Diabetes in Denmark: A Decision-Analytic Modelling Study
por: Pulleyblank, Ryan, et al.
Publicado: (2023)

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2016)

Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”
por: Lopes, Sandra, et al.
Publicado: (2020)

Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials
por: Iqbal, Nayyar, et al.
Publicado: (2014)

Randomized Clinical Trial on Efficacy of Empagliflozin Versus Sitagliptin, In Addition to Metformin in Type 2 Diabetic Patients
por: Mubashir, Muaz, et al.
Publicado: (2022)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

A Comparison of the Effects of Empagliflozin and Sitagliptin, When Combined With Metformin, on Lipid Levels in Patients with Type 2 Diabetes: A Clinical Investigation
por: Ahmed, Mazhar, et al.
Publicado: (2023)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
por: Nilsson, Kristoffer, et al.
Publicado: (2022)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up
por: Nakamura, Takashi, et al.
Publicado: (2016)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
por: Li, Chun-Jun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nm5bo5im71g8sm555dpdbr7rcg